CD38 and acute myeloid leukemia: Daratumumab, a monoclonal anti-CD38 antibody approved for the treatment of multiple myeloma, was shown to block the delivery of mitochondria to AML cells, decrease the oxygen consumption rate, and inhibit the growth of leukemic cells [128, 129].